The global market for IVUS catheters reached a valuation of over $255 million in 2022 and is projected to grow at a CAGR of 8.4% during the forecast period, reaching nearly $451 million.
IVUS catheters are utilized in conjunction with various minimally invasive cardiovascular devices. They are predominantly employed in angioplasty procedures, either before, during, or after the intervention. It is important to note that these procedures necessitate the availability of an IVUS console within catheterization laboratories (cath labs).
Philips emerged as the leading competitor in the market, offering the Eagle Eye Platinum™ and Revolution™ IVUS catheter product lines that are compatible with their Core™ and Core Mobile™ IVUS console product lines. These consoles provide options for fractional flow reserve (FFR), instantaneous wave-free ratio (IFR), and IVUS modalities in a single platform. Philips is expected to leverage its strong presence in the coronary balloon catheter market to maintain its leading position in the IVUS market.
Boston Scientific, on the other hand, secured the second-leading position in the global IVUS catheter market in 2022. The company introduced its OptiCross™ IVUS device, which received clearance from the FDA, CE Mark, and approval from Japan PMDA, allowing its availability in the U.S., Europe, and Japan, respectively. The OptiCross™ IVUS device was designed with input from physicians worldwide, aiming to improve functionality during complex cases. Boston Scientific's effective coordination of sales between its drug-eluting stents and IVUS catheters further strengthens its competitive position in the market.
IVUS catheters are utilized in conjunction with various minimally invasive cardiovascular devices. They are predominantly employed in angioplasty procedures, either before, during, or after the intervention. It is important to note that these procedures necessitate the availability of an IVUS console within catheterization laboratories (cath labs).
DATA TYPES INCLUDED
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Angiography and PCI Procedure Volumes
- Market Forecasts Until 2029, and Historical Data to 2022
- Market Drivers & Limiters for Each Global IVUS market
- Competitive Analysis with Market Shares for Each Segment
- Recent Mergers & Acquisitions
- COVID19 Impact on the Global Coronary IVUS Market
- Disease Overviews and Demographic Information
- Company Profiles, Product Portfolios and SWOT for Top Competitors
GLOBAL INTRAVASCULAR ULTRASOUND CATHETER MARKET INSIGHTS
The adoption of intravascular imaging technologies, including IVUS and OCT, is witnessing a growing trend, with both technologies competing for popularity. As alternative options to angiography, this competition is projected to have a limiting effect on market growth. However, as physician training and clinical awareness regarding IVUS continue to improve, there is an increasing penetration of procedures utilizing this technology. This standardized utilization, along with the anticipated rise in market value, is expected to be driven by the growing acceptance of IVUS worldwide, although North America and Asia Pacific currently lead in device adoption. Other regions across the globe are gradually embracing this technology as well.GLOBAL INTRAVASCULAR ULTRASOUND CATHETER MARKET SHARE INSIGHTS
In 2022, the global IVUS catheter market was primarily dominated by two key players, namely Philips and Boston Scientific.Philips emerged as the leading competitor in the market, offering the Eagle Eye Platinum™ and Revolution™ IVUS catheter product lines that are compatible with their Core™ and Core Mobile™ IVUS console product lines. These consoles provide options for fractional flow reserve (FFR), instantaneous wave-free ratio (IFR), and IVUS modalities in a single platform. Philips is expected to leverage its strong presence in the coronary balloon catheter market to maintain its leading position in the IVUS market.
Boston Scientific, on the other hand, secured the second-leading position in the global IVUS catheter market in 2022. The company introduced its OptiCross™ IVUS device, which received clearance from the FDA, CE Mark, and approval from Japan PMDA, allowing its availability in the U.S., Europe, and Japan, respectively. The OptiCross™ IVUS device was designed with input from physicians worldwide, aiming to improve functionality during complex cases. Boston Scientific's effective coordination of sales between its drug-eluting stents and IVUS catheters further strengthens its competitive position in the market.
REPORT REGIONAL COVERAGE
Throughout this research series, the author has extensively covered several regions. The regions covered in our research include:- North America (the United States and Canada)
- Latin America (Brazil, Mexico, Colombia, Argentina, Peru, Chile, Venezuela, and Other)
- Western Europe (Germany, France, Italy, Spain, Switzerland, Austria, Portugal, Benelux, Scandinavia, and Other)
- Central and Eastern Europe (Poland, Turkey, Russia, Greece, Czech Republic, Croatia, Bulgaria, Ukraine, Kazakhstan, Hungary, Romania, Baltic States (Estonia, Latvia, and Lithuania), and Other)
- Middle East (Saudi Arabia, UAE, Israel, Iran, Kuwait, Qatar, Bahrain, Oman, and Other)
- Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Indonesia, Malaysia, Thailand, the Philippines, Brunei, Myanmar, Cambodia, Vietnam, New Zealand, Taiwan, Hong Kong, and Other)
- Africa (South Africa, Egypt, Morocco, Ghana, Nigeria, Libya, Sudan, Uganda, Kenya, and Other)
Table of Contents
Intravascular Ultrasound Catheter Market
List of Charts
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ACIST Medical Systems
- Boston Scientific
- Infraredx
- Philips
